Hebrew University of Jerusalem, BioTheryX deal

The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A; CKI-alpha) inhibitors to treat hematologic and solid malignancie...